11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

OTR Global has a Positive read on Tandem Diabetes (TNDM) and Insulet (PODD) after interviews with U.S. endocrinology practitioners that showed ...

Citi raised the firm’s price target on Insulet to $310 from $283 and keeps a Buy rating on the shares as part of a 2025 outlook for the U.S.

In this video, Joseph Hog discusses growth stocks that offer potential for triple-digit returns without the risk of ...

From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect ...

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

Insulin pump maker Insulet won $452 million in its trade secret case against Korean rival EOFlow, the company announced on ...

The company said it had restarted production of intravenous solutions on two lines in November, and added they were manufacturing 1-liter IV solution bags, the most commonly used size by hospitals and ...

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

This briefing covers significant developments in health, including a revised deal between GSK and China's Zhifei, FDA ...